Â鶹ԭ´´

Table 1ÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌý Open Phase I/II Clinical Trials with Adaptimmune’s NY-ESOc259T
Table 2ÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌý Planned clinical study at Dana Farber Cancer Institute with autologous T-cells expressing chimeric NKG2D receptor
Table 3ÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌý Pipeline of TCR T-Cell Product Candidates from Companies
Table 4ÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌý Pipeline of CD19 CAR T-cell product candidates from Companies
Table 5ÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌý Pipeline of Hematologic CAR T-cell product candidates from Companies
Table 6ÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌý Pipeline of Solid Tumor CAR T-cell product candidates from Companies
Table 7ÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌý Pipelines of NK cells, TILs, DLIs & CTLs from Companies
Table 8ÌýÌýÌýÌýÌýÌýÌýÌýÌýÌýÌý Open Phase I/II Clinical Trials with Adaptimmune’s NY-ESOc259T
Table 9 ÌýÌýÌýÌýÌýÌýÌýÌýÌýÌý Bellicum’s Pipeline of Cellular Product Candidates
Table 10ÌýÌýÌýÌýÌýÌýÌýÌýÌý Cardio3 BioSciences‘ R&D Pipeline of CAR T-Cells
Table 11ÌýÌýÌýÌýÌýÌýÌýÌýÌý Cellectis R&D Pipeline of UCARTs
TableÌý 12 ÌýÌýÌýÌýÌýÌýÌý Early clinical trials at PLA General Hospital with autologous CAR T cells
Table 13ÌýÌýÌýÌýÌýÌýÌýÌýÌý Conkwest’s R&D pipeline of Natural Killer Cell-derived Product Candidates
Table 14ÌýÌýÌýÌýÌýÌýÌýÌýÌý Goals and terms of Immunocore’s partnering deals for ImmTAC technology
Table 15ÌýÌýÌýÌýÌýÌýÌýÌýÌý CAR Pipeline of ZIOPARM Oncology & Intrexon & MD Anderson
Table 16 ÌýÌýÌýÌýÌýÌýÌýÌý Profiles of Juno’s lead CD19-directed T-cell product candidates
Table 17ÌýÌýÌýÌýÌýÌýÌýÌýÌý Juno’s Pipeline of CAR and TCR T cell product candidates
Table 18ÌýÌýÌýÌýÌýÌýÌýÌýÌý Kite Pharma’s Pipeline of CAR and TCR T cell product candidates
Table 19ÌýÌýÌýÌýÌýÌýÌýÌýÌý Lion’s Pipeline of autologous Tumor Infiltration Lymphocytes
Table 20ÌýÌýÌýÌýÌýÌýÌýÌýÌý Clinical studies at MD Anderson with 2nd generation CD19 CAR T-cells co-activating via chimeric CD3z/CD28
Table 21ÌýÌýÌýÌýÌýÌýÌýÌýÌý Takara Bio’s Pipeline of TCR and CAR T cell product candidates
Table 22ÌýÌýÌýÌýÌýÌýÌýÌýÌý Clinical study in Singapore with 3rd generation universal ACTR T-cells CD16V-BB-ζÌý in combination with rituximab
Table 23ÌýÌýÌýÌýÌýÌýÌýÌýÌý Novartis‘ Pipeline of autologous CAR T-cell product candidates
Table 24ÌýÌýÌýÌýÌýÌýÌýÌýÌý Major terms of collaboration between Cellectis and Pfizer
Table 25ÌýÌýÌýÌýÌýÌýÌýÌýÌý Major terms of collaboration between Cellectis and Servier
Table 26ÌýÌýÌýÌýÌýÌýÌýÌýÌý Competitive Profiles of the five most advanced CAR / TCR T-Cell Companies
Table 27ÌýÌýÌýÌýÌýÌýÌýÌýÌý Competitive Profiles of emerging or non-US CAR / TCR T-Cell Companies
Table 28ÌýÌýÌýÌýÌýÌýÌýÌýÌý Companis providing technology in the CAR T Cell Therapy field
Table 29ÌýÌýÌýÌýÌýÌýÌýÌýÌý TCR and CAR Deals between Pharma and Biotech
Table 30ÌýÌýÌýÌýÌýÌýÌýÌýÌý Scope of Interest of Pharma Deals for TCR & CAR Immunotherapeutics
Table 31ÌýÌýÌýÌýÌýÌýÌýÌýÌý Alternative T Cell and Natural Killer Cell Immunotherapeutics
Table 32ÌýÌýÌýÌýÌýÌýÌýÌýÌý TCR and CAR Deals between Pharma and Biotech
Table 33ÌýÌýÌýÌýÌýÌýÌýÌýÌý Economic Terms of TCR and CAR Deals between Pharma and Biotech
Table 34ÌýÌýÌýÌýÌýÌýÌýÌýÌý Biotech – Biotech Deals in the field of TCR and CAR Immunotherapeutics
Table 35ÌýÌýÌýÌýÌýÌýÌýÌýÌý Private Financing Rounds of Companies with TCR or CAR Immunotherapeutics
Table 36ÌýÌýÌýÌýÌýÌýÌýÌýÌý Public Offering & Â鶹ԭ´´ Capitalization of Companies with TCR or CAR Immunotherapeutics
Table 37ÌýÌýÌýÌýÌýÌýÌýÌýÌý Opportunities for novel TCR and CAR Immunotherapeutics